1044871-36-4

Basic information

• Product Name: 6-bromo-2-(4-hydroxy-3,5-dimethylphenyl)quinazolin-4(3H)-one
• Synonyms: 6-bromo-2-(4-hydroxy-3,5-dimethylphenyl)quinazolin-4(3H)-one
• CAS NO: 1044871-36-4
• Molecular Weight: 345.195
• Mol File: 1044871-36-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6-bromo-2-(4-hydroxy-3,5-dimethylphenyl)quinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-2-(4-hydroxy-3,5-dimethylphenyl)quinazolin-4(3H)-one(1044871-36-4)
• EPA Substance Registry System: 6-bromo-2-(4-hydroxy-3,5-dimethylphenyl)quinazolin-4(3H)-one(1044871-36-4)

Safety Data

• Hazardous Substances Data: 1044871-36-4(Hazardous Substances Data)

Upstream product

• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 16313-66-9 5-bromoanthranilamide 
• 4919-37-3 3,5-dimethyl-4-hydroxybenzoic acid 

Downstream Products

• 1253731-94-0 2-(4-hydroxy-3,5-dimethylphenyl)-6-vinylquinazolin-4(3H)-one 
• 1253731-93-9 2-(4-hydroxy-3,5-dimethylphenyl)-6-[(4-methylpiperazin-1-yl)methyl]quinazolin-4(3H)-one 
• 1253731-95-1 2-(4-hydroxy-3,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazoline-6-carbaldehyde 

Relevant articles and documents

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation

Bromodomain-containing protein 4 (BRD4) represents a promising drug target for anti-inflammatory therapeutics. Herein, we report the design, synthesis, and pharmacological evaluation of novel chromone derivatives via scaffold hopping to discover a new class of orally bioavailable BRD4-selective inhibitors. Two potent BRD4 bromodomain 1 (BD1)-selective inhibitors 44 (ZL0513) and 45 (ZL0516) have been discovered with high binding affinity (IC50 values of 67-84 nM) and good selectivity over other BRD family proteins and distant BD-containing proteins. Both compounds significantly inhibited the expression of Toll-like receptor-induced inflammatory genes in vitro and airway inflammation in murine models. The cocrystal structure of 45 in complex with human BRD4 BD1 at a high resolution of 2.0 ? has been solved, offering a solid structural basis for its binding validation and further structure-based optimization. These BRD4 BD1 inhibitors demonstrated impressive in vivo efficacy and overall promising pharmacokinetic properties, indicating their therapeutic potential for the treatment of inflammatory diseases.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.